Scholar Rock's Dual-Path Apitegromab Approval: Two Facilities, One PDUFA, and a Launch on the Horizon
As the September 30 PDUFA approaches, Scholar Rock executes on a second fill/finish facility, commercial readiness, and a strong cash position.
SRRK · Earnings Call · 2026-08-06
Approval Clock Ticking with Two Independent Paths
Scholar Rock is in the final stretch of its long road to bring apitegromab, a muscle-targeting therapy for spinal muscular atrophy (SMA), to patients. The company's second-quarter call on August 6 was dominated by the September 30 PDUFA date and the progress of its dual fill/finish facility strategy. David Hallal, CEO, framed the moment: “We are on the threshold of bringing the world's first muscle-targeted therapy to children and adults living with SMA.” — David Hallal, Board Chair and Chief Executive Officer · 2026-08-06 The BLA resubmission includes both Catalent Indiana and a second facility, offering two independent paths to approval. Hallal emphasized the optionality: “We now have more vials available from this facility than we do from Catalent Indiana.” — David Hallal, Board Chair and Chief Executive Officer · 2026-08-06 The second facility has passed recent inspections and has product at a third-party packaging site. The company remains in close contact with the FDA, with the inspection classification for Catalent still pending.
Both Catalent Indiana and our second facility are now on site at our third-party provider awaiting packaging and labeling upon approval.
Akshay Vaishnaw, President of R&D, reiterated confidence in meeting the PDUFA, stating: “There is no reason to believe the FDA can't get their work done in these next 55 days.” — Akshay Vaishnaw, President of R&D · 2026-08-06 The fill/finish facility strategy has been the core of the turnaround from last year's CRL, and the second facility provides substantial supply.
Launch Readiness: From Field Teams to Payer Conversations
The commercial organization is primed. Keith Woods, COO, detailed the extensive preparation: "We are ready to launch apitegromab at any time prior to and including our September 30 PDUFA date." The field team has engaged with approximately 140 SMA treatment centers and 2,600 prescribing physicians. Payer discussions are progressing, with an expectation that prior authorization and a J-code will be part of the initial reimbursement landscape. Woods noted the time to get patients on therapy could exceed 60 days. “The team is kind of chomping at the bit to really get out there and launch this product.” — Robert Keith Woods, Chief Operating Officer · 2026-08-06 The company's launch readiness extends to Europe, with Germany as the initial market.
The early access program and open-label extension patients will be the first to convert. This prepared stance reflects lessons from the earlier delay. As Hallal said in a prior call, “Let's do better this time than we did last time.” — David Hallal, Chairman and Chief Executive Officer · 2026-05-07 That sentiment underscores the operational overhaul that has been underway.
Financial Strength and Pipeline Momentum
Scholar Rock ended Q2 with $492 million in cash, including $63 million from its ATM program, and retains an option to draw an additional $150 million from its debt facility. “We ended the second quarter with $492 million in cash, cash equivalents and marketable securities.” — Vikas Sinha, Chief Financial Officer · 2026-08-06 This runway supports both commercial launch and pipeline investment. The company's cash runway stands at 5.9 quarters, providing ample time to execute the launch. R&D spending continues on the Phase II OPAL study in infants, the newly initiated FORGE trial in FSHD, and SRK-439. The apitegromab BLA is the critical asset, but the pipeline extends beyond it, leveraging the anti-myostatin platform.
The financial discipline is evident despite rising operating expenses, which were $108.9 million in the quarter, including stock-based compensation. The company is balancing launch readiness with pipeline advancement, a theme echoed in prior calls. As Vikas Sinha noted in March, “We will follow most likely the normal rare disease kind of revenue trajectory.” — Vikas Sinha, Chief Financial Officer · 2026-03-03 The balance sheet remains a key strength as the company approaches its inflection point.